Abstract
In view of the emerging clinical indications for Phosphodiesterase 9 inhibitors e.g. treatment of Alzheimer, diabetes, cancer, and the limited number of its selective inhibitors which possess a single chemical scaffolds, a structure-based approach was undertaken to mine the ZINC database by virtual screening to identify novel PDE9 inhibitors. The database, which was never reported to have been used before for discovery of PDE9 inhibitors, was screened against the ligand binding pocket of the PDE9 complex (PDB:4GH6) using molecular docking programs, MOE and AutoDock Vina in PyRx. Three different scoring functions were used to evaluate the docking poses and scores of the compounds, and the compounds were selected through consensus selection, thus reducing the margin of error in docking. The highest scoring compounds were then selected and purchased for in vitro testing as PDE9 inhibitors and cancer growth inhibitory agents. This led to the discovery of three previously unreported potent PDE 9 inhibitory compounds with two unique chemical scaffolds. Consistent with the role of PDE9 in cancer cell growth, the compounds also inhibited the growth of breast tumor cell lines, MCF-7 and MDA-468 at concentrations comparable to those that inhibited PDE9.
Keywords: Phosphodiesterase 9 inhibitors, virtual screening, ZINC database.
Medicinal Chemistry
Title:Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach
Volume: 12 Issue: 5
Author(s): Engi A. Hassaan, Sara C. Sigler, Tamer M. Ibrahim, Kevin J. Lee, Lauren K. Cichon, Bernard D. Gary, Joshua C. Canzoneri, Gary A. Piazza and Ashraf H.Abadi
Affiliation:
Keywords: Phosphodiesterase 9 inhibitors, virtual screening, ZINC database.
Abstract: In view of the emerging clinical indications for Phosphodiesterase 9 inhibitors e.g. treatment of Alzheimer, diabetes, cancer, and the limited number of its selective inhibitors which possess a single chemical scaffolds, a structure-based approach was undertaken to mine the ZINC database by virtual screening to identify novel PDE9 inhibitors. The database, which was never reported to have been used before for discovery of PDE9 inhibitors, was screened against the ligand binding pocket of the PDE9 complex (PDB:4GH6) using molecular docking programs, MOE and AutoDock Vina in PyRx. Three different scoring functions were used to evaluate the docking poses and scores of the compounds, and the compounds were selected through consensus selection, thus reducing the margin of error in docking. The highest scoring compounds were then selected and purchased for in vitro testing as PDE9 inhibitors and cancer growth inhibitory agents. This led to the discovery of three previously unreported potent PDE 9 inhibitory compounds with two unique chemical scaffolds. Consistent with the role of PDE9 in cancer cell growth, the compounds also inhibited the growth of breast tumor cell lines, MCF-7 and MDA-468 at concentrations comparable to those that inhibited PDE9.
Export Options
About this article
Cite this article as:
A. Hassaan Engi, C. Sigler Sara, M. Ibrahim Tamer, J. Lee Kevin, K. Cichon Lauren, D. Gary Bernard, C. Canzoneri Joshua, A. Piazza Gary and H.Abadi Ashraf, Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach, Medicinal Chemistry 2016; 12 (5) . https://dx.doi.org/10.2174/1573406412666151204002836
DOI https://dx.doi.org/10.2174/1573406412666151204002836 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Environmental Exposure, and Other Behavioral Risk Factors in Breast Cancer
Current Cancer Therapy Reviews Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Heterocyclic Compounds as MDR Modulators
Letters in Drug Design & Discovery Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
Letters in Drug Design & Discovery miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Circadian Rhythm and Concentration of Melatonin in Breast Cancer Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface: A New Era of Nanoimmunology
Current Pharmaceutical Biotechnology Design, Sar, and Metabolism Study of Crucifereae Family Compound (Spirobrassinin) and its Analogs for Antiangiogenic Potential Targeting Hsp90
Current Proteomics Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery Telomerase Inhibition and Cancer: Might Platinum Based Drugs have a Future as Anti-telomerase Pharmacological Approach?
Current Medicinal Chemistry Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Potential Clinical Applications of (-), (+) and (±)-Z-Bisdehydrodoisynolic Acids in Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Evidence of Probiotics in Prevention of Allergy and Asthma
Current Drug Targets - Inflammation & Allergy